Redeye leaves a comment on the Q1 report published by Alzinova earlier today. Overall, the report was in line with our expectations. However, we are encouraged by the clinical and financial progress of the company during the period. We reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10 as we continue to have a positive outlook on the case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/